Skip to main content

Table 2 Respiratory Function

From: High-dose methylprednisolone pulse therapy during refractory COVID-19 acute respiratory distress syndrome: a retrospective observational study

Parameter

 

ICU-Admission

(N = 37)

MPT (N = 37)

3 days post MPT (N = 32)

10 days post MPT (n = 24)

14 days post MPT (n = 22)

p-value

FiO2[%]

 

77 ± 19

77 ± 22

62 ± 23

58 ± 26#

(p = 0.024)

67 ± 25 (N = 19)

0.007

paO2/FiO2

 

110 ± 54

116 ± 44

151 ± 65*

(p = 0.034)

151 ± 60*

(p = 0.031)

149 ± 64 (N = 21)

0.006

Tidal Volume [ml]

 

480 ± 251 (N = 24)

335 ± 259 (N = 24)

403 ± 219 (N = 21)

326 ± 172 (N = 19)

294 ± 175§ (N = 15)

0.044

Driving Pressure [cmH2O]

 

11 ± 8 (N = 24)

13 ± 5 (N = 24)

13 ± 6 (N = 20)

15 ± 5 (N = 15)

15 ± 5 (N = 11)

0.202

Compliance

[ml/cmH2O]

 

29 ± 29 (N = 21)

21 ± 24 (N = 23)

31 ± 38 (N = 17)

16 ± 10 (N = 13)

15 ± 12 (N = 10)

0.112

Mechanical Power [J/min]

 

30 ± 27

(N = 24)

20 ± 14(N = 24)

23 ± 14 (N = 19)

18 ± 13 (N = 12)

16 ± 15 (N = 10)

0.193

CRP [mg/dl]

 

8.6 ± 9.6

5.7 ± 7.3

2.9 ± 4.0*# (*p = 0.005; #p = 0.007)

6.1 ± 7.7

5.5 ± 5.7

0.002

Ventilation Mode n [%]

Spontaneous Breathing

0

1 (3)

0

5 (21)

6 (27)

0.001

 

O2-Insufflation

3 (8)

0

2 (6)

0

1 (5)

 

High-Flow O2

10 (27)

12 (32)

9 (28)

4 (17)

4 (18)

 

PSV

5 (14)

9 (24)

10 (31)

6 (25)

2 (9)

 

PCV

18 (49)

14 (44)

11 (34)

8 (33)

8 (36)

 

APRV

1 (3)

1 (3)

0

1 (4)

1 (5)

 

ECMO

2 (5)

19 (54)

18 (51)

16 (66)

15 (68)

  1. *Significantly different vs. MPT; # significantly different vs. Admission; § significantly different vs. 3 days post MPT
  2. ICU: Intensive Care Unit; MPT: Methylprednisolone Pulse Therapy; FiO2: Fraction of inspired oxygen; paO2: Arterial Partial Pressure of Oxygen; CRP: C-reactive Protein; PSV: Pressure Support Ventilation; PCV: Pressure Control Ventilation; APRV: Airway Pressure Release Ventilation; ECMO: Extracorporeal Membrane Oxygenation